Physician profile
Jonathon D Porter
NPI 1033461884
$2,638.13
in general payments reported to CMS, 2019-2025
22 companies · $20.16 in 2025
The $20.16 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,968 · 2020: $316 · 2021: $194 · 2022: $20.30 · 2023: $59.79 · 2024: $60.24 · 2025: $20.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $307.36 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $298.55 | 2019 | |
| Tris Pharma INC | $244.54 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $222.31 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $212.59 | 2019-2020 | |
| Allergan, INC. | $192.40 | 2019 | |
| Abbvie INC. | $168.73 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $134.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $132.54 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.50 | 2021 | |
| Bausch Health US, LLC | $110.04 | 2019-2022 | |
| Lundbeck LLC | $89.63 | 2019-2020 | |
| Neuronetics, INC. | $75.99 | 2019 | |
| Neos Therapeutics, LP | $66.78 | 2019 | |
| Shire North American Group INC | $58.62 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $49.85 | 2019 | |
| Ironshore Pharmaceuticals INC. | $36.01 | 2019-2020 | |
| Alkermes, INC. | $28.96 | 2024 | Vivitrol |
| Teva Pharmaceuticals USA, INC. | $24.43 | 2019 | |
| Adlon Therapeutics L.P. | $24.26 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.86 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.